Societal Indicators Clause Samples

Societal Indicators. The LMAPD also requires government to report annually on societal indicators of labour market participation of persons with disabilities. Societal indicators include: • employment rate; • education attainment; and • employment earnings.
View SourceView Similar (6)
Societal Indicators. The following information regarding societal indicators has been provided by Human Resources and Skills Development Canada and is based on information from data from Statistics Canada, Survey of Labour and Income Dynamics. For more information about the Survey of Labour and Income Dynamics, visit the Government of Canada Statistics Canada website at ▇▇▇.▇▇▇▇▇▇▇.▇▇.
View SourceView Similar (4)
Societal Indicators. The following charts represent societal indicators of labour market participation for Nova Scotians. These indicators include educational attainment, labour force activity and employment income. The source for the data is the Participation and Activity Limitation ▇▇▇▇▇▇ (▇▇▇▇) ▇▇▇▇▇.
View Source
Societal Indicators. The following charts represent societal indicators of labour market participation for Nova Scotians. Indicators include: educational attainment, labour force activity and employment income. The 2004 baseline report presented societal indicators using data from the Participation and Activity Limitation Survey (PALS), Canada’s principal source of detailed statistical information about disability issues. PALS was first conducted in 2001 and it will be conducted again following the 2006 census. This year’s report uses another important Statistics Canada survey, the Survey of Labour and Income Dynamics (SLID), to present societal indicators. SLID is conducted annually and is a rich source of information about income, employment, education and other topics for the adult Canadian population. SLID tracks the same individuals over a period of years. The SLID data provides information about the education levels, employment earnings and trends within these measures for people with and without disabilities. Charts 1 and 2 show the level of participation and non-participation in the labour force by individuals aged 16 to 64. Individuals are considered employed only if they were employed for the entire year. Similarly, individuals unemployed or not active in the labour force experienced that employment status for the whole year. 1 There have been improvements in the percentage of persons with disabilities participating in the labour force over the seven year period 1999 to 2005. In 2005 47% of persons with disabilities were employed compared to 36% in 1999. Over the same period there was a 6% increase in the numbers of employed persons with out disabilities. People with out disabilities are more likely than persons who are disabled to participate in the labour force - this can be seen in the lower percentages of employed persons with disabilities (Chart 1) and the higher percentage of persons with disabilities who do not participate or are unemployed (Chart 2). 80 70 60 50 40 30 20 10 0 Disabled 1999 2000 2001 2002 2003 2004 2005 All Individuals Not Disabled 80 70 60 50 40 30 20 10 0 1999 2000 2001 2002 2003 2004 2005 All Individuals Disabled Not Disabled
View Source
Societal Indicators. Each year the Canada‐Nova Scotia Labour Market Agreement for Persons with Disabilities reports have included societal indicators using data from the Participation and Activity Limitation Survey (PALS), when available, and the Survey of Labour and Income Dynamics (SLID). Human Resources Skills Development provides the societal indicators data for the annual reports each September16. This report includes SLID data from 1999 thru 2010 for most of the societal indicators. The SLID is a longitudinal survey, interviewing the same panel of respondents each year over a period of six years. It tracks overlapping panels of individual respondents and is conducted annually. It is a rich source of information about income, employment, education and other characteristics of the adult Canadian population. Since the first report in 2004 there have been improvements on some of the societal indicators for persons with disabilities. There has been a steady increase in the educational achievements of working aged adults since 1999. There has been an increase in employment and a decrease in the proportions of persons with disabilities who do not participate in the labour force. As the economy grew between 2001 and 2009, the numbers of persons with disabilities who were able to participate in the labour force increased. Greater participation in the labour force was accompanied by increases in average annual incomes and greater numbers of persons with disabilities with earned income. The constant dollar value of average incomes for persons with disabilities has fluctuated year to year as it increased between 2001 and 2009. Over the same period, the constant dollar value of average incomes for persons who do not have a disability increased steadily from one year to the next. These two trends resulted in a decline in the average earnings (constant dollars) of persons with disabilities expressed as a percentage of the average earnings (constant dollars) of persons who do not have a disability. In 2010 the average earnings of persons with disabilities were equivalent to 85 percent of the average earnings of persons without a disability – 16 2009 was an exception. The data was delayed and subsequently reported in an updated release February 2010
View Source

Related to Societal Indicators

  • Licensed Product The term “Licensed Product” shall mean any product (a) the manufacture, use, importation, sale or offer for sale of which would, in the absence of the license granted by this Agreement, infringe a Valid Claim of any of the Licensed Patent Rights, or (b) that is comprised of, utilizes or incorporates Licensed Biological Materials, or (c) that is discovered, developed or made using a Licensed Process.

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement or the Prospectus, or the results of which are referred to in the Registration Statement or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMA, Health Canada and other comparable regulatory agencies outside of the U.S. to which they are subject, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58, 312, and 812; the descriptions of the results of such studies, tests and trials contained in the Registration Statement or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement or the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.